NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial.
Saved in:
| Title: | NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. |
|---|---|
| Authors: | Gao C; Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Zhang Y; Department of Gastroenterology Ward ll, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China., Qu X; Department of Medical Oncology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China., Chen X; Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Zhang J; Department of Gastroenterology Ward II, Liaoning Cancer Hospital, Shenyang, Liaoning, China., Wu H; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China., Sun M; Department of Oncology, Jinan Central Hospital, Jinan, Shandong, China., Zha Y; Hepatobiliary Pancreatic Surgery, Yunnan Cancer Hospital, Kunming, Yunnan, China., Wang J; The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China., Wang Y; Oncology Gastroenterology Department, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China., Li Z; Department of Medical Oncology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China., Gao J; Department of Medical Oncology, Cangzhou Central Hospital, Cangzhou, Hebei, China., Lin R; Department of Gastrointestinal Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, China., Zang A; Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, Hebei, China., Zhang H; Department of Gastroenterology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China., Yuan X; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China., Du C; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China., Zhao J; Department of Oncology, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China., Yang Y; Department of Hepatobiliary and Pancreatic Surgery, Second Hospital of Jilin University, Changchun, Jilin, China., Shi X; Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China., Cheng W; Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, Changsha, Hunan, China., Wang B; Department of Gastroenterology, General Hospital of Tianjin Medical University, Tianjin, China., Wu S; Department of Medical Oncology, Peking University First Hospital, Beijing, China., Zhao T; Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Wang J; Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Gao S; Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Wang X; Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Ma W; Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Liu R; Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Shi Y; Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Liu Y; Clinical Development Division, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, Hebei, China., Xie Y; Clinical Development Division, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, Hebei, China., Niu M; Clinical Development Division, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, Hebei, China., Zhao F; Clinical Development Division, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, Hebei, China., Yu J; Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China. yujun@tjmuch.com., Hao J; Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China. haojihui@tjmuch.com. |
| Source: | Nature communications [Nat Commun] 2026 Jan 16; Vol. 17 (1), pp. 1715. Date of Electronic Publication: 2026 Jan 16. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
